These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1470 related items for PubMed ID: 3257715

  • 1. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
    Kawase I, Komuta K, Hara H, Inoue T, Hosoe S, Ikeda T, Shirasaka T, Yokota S, Tanio Y, Masuno T.
    Cancer Res; 1988 Mar 01; 48(5):1173-9. PubMed ID: 3257715
    [Abstract] [Full Text] [Related]

  • 2. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors.
    Maekawa R, Kitagawa T, Koizumi K, Sato K, Homma M.
    J Biol Response Mod; 1989 Dec 01; 8(6):676-90. PubMed ID: 2600605
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Synergistic antitumor effects of BCG and monoclonal antibodies capable of inducing antibody-dependent cell-mediated cytotoxicity.
    Komuta K, Kawase I, Ogura T, Masuno T, Yokota S, Hosoe S, Ikeda T, Shirasaka T, Kishimoto S.
    Jpn J Cancer Res; 1987 Feb 01; 78(2):185-92. PubMed ID: 3104261
    [Abstract] [Full Text] [Related]

  • 5. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
    Shiloni E, Eisenthal A, Sachs D, Rosenberg SA.
    J Immunol; 1987 Mar 15; 138(6):1992-8. PubMed ID: 3493293
    [Abstract] [Full Text] [Related]

  • 6. IL-4 regulation of murine lymphokine-activated killer activity in vitro. Effects on the IL-2-induced expansion, cytotoxicity, and phenotype of lymphokine-activated killer effectors.
    Mulé JJ, Krosnick JA, Rosenberg SA.
    J Immunol; 1989 Jan 15; 142(2):726-33. PubMed ID: 2783444
    [Abstract] [Full Text] [Related]

  • 7. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three district histological types.
    Papa MZ, Mulé JJ, Rosenberg SA.
    Cancer Res; 1986 Oct 15; 46(10):4973-8. PubMed ID: 3489517
    [Abstract] [Full Text] [Related]

  • 8. Characteristics of murine non-specific killer cells induced in vivo by recombinant human interleukin-2.
    Hinuma S, Naruo K, Shiho O, Tsukamoto K.
    Immunology; 1986 Oct 15; 59(2):251-9. PubMed ID: 3490435
    [Abstract] [Full Text] [Related]

  • 9. Murine lymphokine-activated killer (LAK) cells: phenotypic characterization of the precursor and effector cells.
    Yang JC, Mulé JJ, Rosenberg SA.
    J Immunol; 1986 Jul 15; 137(2):715-22. PubMed ID: 2873187
    [Abstract] [Full Text] [Related]

  • 10. Effect of combined therapy with lymphokine-activated killer cells, interleukin 2 and specific monoclonal antibody on established B16 melanoma lung metastases.
    Eisenthal A, Cameron RB, Uppenkamp I, Rosenberg SA.
    Cancer Res; 1988 Dec 15; 48(24 Pt 1):7140-5. PubMed ID: 3263900
    [Abstract] [Full Text] [Related]

  • 11. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
    Mulé JJ, Ettinghausen SE, Spiess PJ, Shu S, Rosenberg SA.
    Cancer Res; 1986 Feb 15; 46(2):676-83. PubMed ID: 3484431
    [Abstract] [Full Text] [Related]

  • 12. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
    Vujanovic NL, Herberman RB, Olszowy MW, Cramer DV, Salup RR, Reynolds CW, Hiserodt JC.
    Cancer Res; 1988 Feb 15; 48(4):884-90. PubMed ID: 3257412
    [Abstract] [Full Text] [Related]

  • 13. Suppression of pulmonary tumour metastasis in mice by recombinant human interleukin-2: role of asialo GM1-positive cells.
    Hinuma S, Naruo K, Ootsu K, Houkan T, Shiho O, Tsukamoto K.
    Immunology; 1987 Feb 15; 60(2):173-9. PubMed ID: 3493209
    [Abstract] [Full Text] [Related]

  • 14. In vivo effects of recombinant human interleukin 2 on antitumor and antiviral natural immunity in induced or natural murine immunodeficiency states.
    Butler LD, Browne CP, Layman NK, Riedl P, Tang J, Marder P, DeLong D, Manetta J, Bobbitt L, Strnad J.
    Cancer Res; 1988 Nov 01; 48(21):6081-9. PubMed ID: 3048654
    [Abstract] [Full Text] [Related]

  • 15. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T, Belfrage H, Bhiladvala P, Hedlund G.
    J Immunol; 1987 Jun 01; 138(11):3640-5. PubMed ID: 3495566
    [Abstract] [Full Text] [Related]

  • 16. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
    Shiloni E, Lafreniere R, Mulé JJ, Schwarz SL, Rosenberg SA.
    Cancer Res; 1986 Nov 01; 46(11):5633-40. PubMed ID: 3489526
    [Abstract] [Full Text] [Related]

  • 17. Monoclonal antibody therapy of murine lymphoma: enhanced efficacy by concurrent administration of interleukin 2 or lymphokine-activated killer cells.
    Schultz KR, Klarnet JP, Peace DJ, Cheever MA, Badger CC, Bernstein ID, Greenberg PD.
    Cancer Res; 1990 Sep 01; 50(17):5421-5. PubMed ID: 2386946
    [Abstract] [Full Text] [Related]

  • 18. Potentiation by interleukin 2 of Burkitt's lymphoma therapy with anti-pan B (anti-CD19) monoclonal antibodies in a mouse xenotransplantation model.
    Vuist WM, v Buitenen F, de Rie MA, Hekman A, Rümke P, Melief CJ.
    Cancer Res; 1989 Jul 15; 49(14):3783-8. PubMed ID: 2472198
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Murine tumor cell lysis by antibody-dependent macrophage-mediated cytotoxicity using syngeneic monoclonal antibodies.
    Kawase I, Komuta K, Ogura T, Fujiwara H, Hamaoka T, Kishimoto S.
    Cancer Res; 1985 Apr 15; 45(4):1663-8. PubMed ID: 3978634
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 74.